SCHEMBL3252526

SCHEMBL3252526

CN(C)CCc1c2n(c3c(C(F)(F)F)cccc13)Cc1ccccc1-2

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 11/20 0.40
▸ MTNR1B P49286 11/20 0.40
▸ HTR6 P50406 2/20 0.38
▸ CYP2D6 P10635 2/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ HRH1 P35367 1/20 0.34
▸ LIPG Q9Y5X9 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.33
▸ ACP1 P24666 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253659 0.85 MTNR1A (0.42) MTNR1AMTNR1BHTR6CYP2D6HTR2A
SCHEMBL3251948 0.83 MTNR1A (0.42) MTNR1AMTNR1BHTR6
SCHEMBL3251139 0.83 MTNR1A (0.42) MTNR1AMTNR1BHTR6
SCHEMBL3253753 0.82 MTNR1A (0.45) MTNR1AMTNR1BHTR6CYP2D6CYP1A2
SCHEMBL3250887 0.82 HTR7 (0.43) MTNR1AMTNR1BHTR6CYP2D6HTR2A
Dimethylamine SCHEMBL3252531 0.82 MTNR1A (0.40) MTNR1AMTNR1BCYP2D6CYP1A2CYP2C9
SCHEMBL3253540 0.78 MTNR1A (0.61) MTNR1AMTNR1BHTR6
SCHEMBL3248299 0.77 MTNR1A (0.40) MTNR1AMTNR1BHTR6CYP2D6HTR2A
SCHEMBL3251527 0.77 MTNR1A (0.39) MTNR1AMTNR1BHTR6CYP2D6HTR2A
SCHEMBL3253643 0.76 MTNR1A (0.39) MTNR1AMTNR1BHTR6CYP2D6HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537113-B9 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2010-05-26 — — EP claimed
EP-1537113-B1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2009-10-07 — — EP claimed
US-7297711-B2 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2007-11-20 — — US claimed
US-20050203103-A1 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-09-15 — — US claimed
EP-1537113-A1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Pharmaceuticals Ltd. (IN) 2005-06-08 — — EP claimed
WO-2004000845-A1 ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO claimed
EP-1537113-B9 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2010-05-26 — — EP disclosed
EP-1537113-B1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2009-10-07 — — EP disclosed
US-7297711-B2 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2007-11-20 — — US disclosed
US-20050203103-A1 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-09-15 — — US disclosed
EP-1537113-A1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Pharmaceuticals Ltd. (IN) 2005-06-08 — — EP disclosed
WO-2004000845-A1 ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203103-A1 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them TPH1, HTR1A, HTR7 MTNR1A 76/4885MTNR1B 105/4885HTR6 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback